Even though there are no biological markers of depression the clinical presentation is very characteristic and used to make a reliable diagnosis. According to the Diagnostic and Statistical Manual of Mental Disorders of the Amercan Psychiatric Association (DSM-IV), 4 the cardinal symptoms of major depression are depressed mood or loss of interest in pleasurable activities (anhedonia) that occur nearly every day for at least 2 weeks, in conjunction with other characteristic symptoms such as alterations in sleep, food intake, body weight, decreased attention, inability to concentrate, feelings of guilt and suicidality.
A patient's eloquent description of how she experienced those diagnostic features of depression brings the disorder to life: 'I did not know what was happening to me. I started to feel an enormous sadness and I started to find that nothing was of interest to me. I stopped exercising, going out with friends, driving, and I dropped out of school. I only wanted to stay home. I felt terrible inside, could not sleep, and had an awful headache, I lost any interest in what I looked like, I would cry all the time, and spent a lot of effort trying to understand myself. I looked at those around me and thought they were all better off than I was. Life seemed to have a limit and I saw no more reason to be alive'. 5 It is usually agreed that once a diagnosis of depression is made, treatment is needed. The question is then: what treatment? While electroconvulsive therapy is extremely effective, 6 it is traditionally reserved for refractory patients due to the need for multiple anesthesias, and possible memory loss. Medications are the first line of treatment for this highly common and complex disorder of unknown cause. While most patients respond well to existing treatments, a substantial minority of those affected do not. Can pharmacogenomics contribute to improve the treatment of depression?
We will cover the multiple steps that occur in antidepressant treatment, identifying the pitfalls that occur along the way and discussing the potential of pharmacogenomics to overcome those obstacles.
DIAGNOSIS
When a depressed person presents to medical care, the physician is confronted with a clinical entity that is very characteristic but for which there is no identified cause, no identified pathognomonic biological abnormality, and no accepted biological marker. A diagnosis is made by clinical observation and the determination that the patient meets a set of standardized criteria that were put together by a committee. 4 Even though the diagnostic criteria have been extensively validated there is more of an element of subjectivity in the diagnosis of depression, particularly in mild cases, than in the diagnosis of medical diseases that are based on objective test criteria such as elevated blood pressure (hypertension) or elevated blood sugar (diabetes mellitus). A key pre-requisite for successful research in pharmacogenomics is accurate phenotype assignment. As single nucleotide polymorphism (SNP) discovery progresses and a successful SNP mapping is put together it is likely that biological and genetic criteria will be identified as contributing markers for the diagnosis of depression.
TREATMENT
After diagnosing depression, the next step is to identify and prescribe a treatment. The choice of medication is probably the area where pharmacogenomics will have its major impact. That will occur in two ways. Pharmacogenomics will contribute to increase available therapeutic targets and to individualize treatment.
IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR DRUG DEVELOPMENT
Existing drugs target mostly monoamines in the brain. A key feature of antidepressant treatment is that the effects on monoamines are nearly immediate, while clinical response takes at least 2-3 weeks to occur. Therefore, it is likely that their rapid effects on monoamines may not be the direct cause of the clinical effects of antidepressants. Moreover, antidepressants of various classes, affecting serotonin, norepinephrine, or dopamine 7, 8 have a common clinical effect. It has been hypothesized that the efficacy of the effects of various types of antidepressants after chronic treatment is due to their effects on new genomic targets. Pharmacogenomics research is being conducted by various groups worldwide to identify novel targets of antidepressants. We have shown by differential mRNA display and validation with reverse Northern blots that new tran-scripts are elicited by chronic antidepressant treatment with drugs of different classes. 9 Currently, the limiting factor in drug development is the identification of new therapeutic targets. This line of investigation will identify targets for the development of new classes of antidepressant drugs.
Individualization of Drug Choice
Importantly, pharmacogenomics will contribute to individualize drug choice by using genotype to predict positive clinical outcomes, adverse reactions, and levels of drug metabolism.
Prediction of Clinical Antidepressant Effects
The serotonin transporter is the initial target of the widely-used selective serotonin reuptake inhibitors (SSRIs). Lesch et al identified a functional polymorphism in the upstream regulatory region that affects transcriptional efficiency. The short variant of the polymorphism reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in decreased 5-HTT expression and 5-HT uptake in lymphoblasts. 10 This polymorphism has been associated with the antidepressant effects of SSRIs and of sleep deprivation. Smeraldi et al studied depressed inpatients who were treated with a fixed dose of fluvoxamine. Both homozygotes for the long variant (l/l) of the 5-HTT promoter and heterozygotes (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s). They concluded that fluvoxamine efficacy in delusional depression seems to be related to allelic variation within the promoter of the 5-HTT gene. 11 The same group found that those carrying two copies of the long variant were also more likely to respond to sleep deprivation, a short-term treatment of depression. 12 In contrast, Kim et al in Korea, studied 120 depressed subjects and showed that those who were homozygous s/s in the promoter region showed better responses than all others. 13 These conflicting results are puzzling, but suggest that this polymorphism may affect antidepress-
The Pharmacogenomics Journal ant treatment response in a different manner in different populations.
Of course, many more polymorphisms in various other genes should be considered. A key dilemma for those investigating this area is whether to intensively examine the effects of as many polymorphisms as possible in a few genes or to set a broader net looking at a few key polymorphisms in a variety of genes. Additional questions of relevance include how to handle the statistical challenges presented by the need for multiple comparisons. Traditional statistical approaches may need to be re-examined. It is likely that pharmacological efficacy in depression will depend on the sum of small effects from multiple genes. As hundreds of SNPs of potential interest are identified, it becomes increasingly difficult to scientifically justify studying just one or a handful of SNPs. On the other hand, if multiple SNPs comparisons are made, the level of statistical correction required for significance will be so high that even contributions of small effect that are occurring at the biological level may not be detected. Novel statistical approaches to handle the assessment of multiple SNPs in large but realistic samples are needed.
Ideal candidates will include antidepressant regulated genes that are discovered by pharmacogenomic studies.
Prediction of Drug Metabolism
Before an antidepressant can exert its effects on central nervous system targets, it must reach those targets in sufficient levels for sufficient time. A variety of genes encoding drug meta- 14 Of particular importance to antidepressant metabolism are cytochrome P 450 enzymes, particularly CYP2D6 (see Table 1 ). CYP2D6 activity is generally lower in Oriental than in Caucasian populations, because of a frequent mutation causing decreased enzyme activity. 15 In contrast, up to 29% of East Africans, particularly Ethiopians, have duplication of the CYP2D6 gene resulting in the translation of multiple copies of the enzyme and in ultrarapid metabolism of drugs that are metabolized by that pathway. 16 Antidepressant treatment of patients with duplication of the CYP2D6 gene may therefore require a very high level of drug for the achievement of adequate bioavailability. The patient's drug metabolizing status should be taken into consideration in the treatment of depression. This is exemplified by the following teaching case:
CYP450 enzymes that metabolize antidepressants
Patient is a 45-year-old research nurse, whose parents are from East Africa. She has a history of major depression and presents to clinic with passive suicidal ideation. Resident, supervised by attending physician, prescribes paroxetine, in regular doses. Patient is seen two weeks after initial visit. Her condition continues to worsen, but she denies any plans to harm self. Because antidepressants can take up to 4-6 weeks to act, and she is not a danger to self, nor others, nor is she gravely disabled, she is scheduled to be seen in two weeks, and instructed to call doctors should symptoms worsen. Ten days later patient committed suicide. Antidepressant levels measured postmortem were barely detectable, in spite of the fact that a pill count from the patient's prescription bottle suggested that she had been taking medication as prescribed. Genetic studies revealed CYP2D6 gene duplication.
This case dramatically illustrates the fact that genetic substrate can have profound effects on drug metabolism, consequently impacting on bioavailability, and treatment efficacy. This is particularly relevant to the treatment of depression, which has the potential to lead to suicide.
CONCLUSIONS
Antidepressant treatment represents an ideal target for pharmacogenomics. Depression is a common disorder affecting over 10% of the North-American population. If inadequately treated, depression can result in suicide, a common cause of death. Treatment for depression is expensive and protracted, and there are no biological markers of treatment response. The identification of genomic markers of treatment response would constitute an enormous clinical advance of public health importance. Moreover, pharmacogenomics may lead to the identification of targets for the development of novel and hopefully more efficacious drugs that have favorable side www.nature.com/tpj effect profiles. Pharmacogenomics can also be used to predict level of drug metabolism and bioavailability, which are key elements of clinical pharmacology.
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